Whole genome sequencing of an African American family highlights toll like receptor 6 variants in Kawasaki disease susceptibility. by Kim, Jihoon et al.
Kim, J; Shimizu, C; Kingsmore, SF; Veeraraghavan, N; Levy, E;
Ribeiro Dos Santos, AM; Yang, H; Flatley, J; Hoang, LT; Hibberd,
ML; Tremoulet, AH; Harismendy, O; Ohno-Machado, L; Burns, JC
(2017) Whole genome sequencing of an African American family high-
lights toll like receptor 6 variants in Kawasaki disease susceptibility.
PLoS One, 12 (2). e0170977. ISSN 1932-6203 DOI: 10.1371/jour-
nal.pone.0170977
Downloaded from: http://researchonline.lshtm.ac.uk/3449720/
DOI: 10.1371/journal.pone.0170977
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: http://creativecommons.org/licenses/by/2.5/
RESEARCH ARTICLE
Whole genome sequencing of an African
American family highlights toll like receptor 6
variants in Kawasaki disease susceptibility
Jihoon Kim1☯*, Chisato Shimizu2☯, Stephen F. Kingsmore3, Narayanan Veeraraghavan3,
Eric Levy1,4, Andre M. Ribeiro dos Santos1, Hai Yang1, Jay Flatley5, Long Truong Hoang6,
Martin L. Hibberd7, Adriana H. Tremoulet2,8, Olivier Harismendy1,9, Lucila Ohno-
Machado1, Jane C. Burns2,8*
1 Department of Biomedical Informatics, University of California San Diego, La Jolla, California, United States
of America, 2 Department of Pediatrics, University of California San Diego, La Jolla, California, United States
of America, 3 Rady Children’s Institute for Genomic Medicine, Rady Children’s Hospital, San Diego,
California, United States of America, 4 Bioinformatics and Systems Biology Graduate Program, University of
California San Diego, La Jolla, California, United States of America, 5 Illumina, San Diego, California, United
States of America, 6 Genome Institute of Singapore, Singapore, Singapore, 7 Depatment of Pathogen
Molecular Biology, London School of Hygiene and Tropical Medicine, London, United Kingdom, 8 Rady
Children’s Hospital San Diego, San Diego, California, United States of America, 9 Moores Cancer Center,
University of California San Diego, La Jolla, California, United States of America
☯ These authors contributed equally to this work.
* j5kim@ucsd.edu (JK); jcburns@ucsd.edu (JCB)
Abstract
Kawasaki disease (KD) is the most common acquired pediatric heart disease. We ana-
lyzed Whole Genome Sequences (WGS) from a 6-member African American family in
which KD affected two of four children. We sought rare, potentially causative genotypes by
sequentially applying the following WGS filters: sequence quality scores, inheritance
model (recessive homozygous and compound heterozygous), predicted deleteriousness,
allele frequency, genes in KD-associated pathways or with significant associations in pub-
lished KD genome-wide association studies (GWAS), and with differential expression in
KD blood transcriptomes. Biologically plausible genotypes were identified in twelve vari-
ants in six genes in the two affected children. The affected siblings were compound hetero-
zygous for the rare variants p.Leu194Pro and p.Arg247Lys in Toll-like receptor 6 (TLR6),
which affect TLR6 signaling. The affected children were also homozygous for three com-
mon, linked (r2 = 1) intronic single nucleotide variants (SNVs) in TLR6 (rs56245262,
rs56083757 and rs7669329), that have previously shown association with KD in cohorts of
European descent. Using transcriptome data from pre-treatment whole blood of KD sub-
jects (n = 146), expression quantitative trait loci (eQTL) analyses were performed. Sub-
jects homozygous for the intronic risk allele (A allele of TLR6 rs56245262) had differential
expression of Interleukin-6 (IL-6) as a function of genotype (p = 0.0007) and a higher eryth-
rocyte sedimentation rate at diagnosis. TLR6 plays an important role in pathogen-associ-
ated molecular pattern recognition, and sequence variations may affect binding affinities
that in turn influence KD susceptibility. This integrative genomic approach illustrates how
the analysis of WGS in multiplex families with a complex genetic disease allows
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examination of both the common disease–common variant and common disease–rare
variant hypotheses.
Introduction
Although the ability to generate whole genome sequences (WGS) from individual subjects has
existed for over a decade, the use of such methods to discover novel disease-causing variants in
multiplexed families affected by complex genetic disease has been limited [1]. However, robust
methods have been developed to identify rare, disease causative variants in WGS of families
with monogenic diseases [2, 3]. Furthermore, such methods have proven useful in identifying
individual patients with common diseases that are caused by rare, highly penetrant variants
[4]. Individuals with rare Mendelian forms of common complex diseases are often distin-
guished by extreme phenotypes–such as very early onset, or disease refractory to usual treat-
ments–and by multiple affected members in single families [5]. Here we sought to test this
hypothesis in a multiplexed family with Kawasaki disease (KD).
Susceptibility to KD, the most common cause of acquired heart disease in children, is pos-
tulated to result from a complex set of genetic variants of which only a limited number have
been validated to date [6]. This self-limited illness of unknown etiology presents with the sud-
den onset of fever and mucocutaneous signs and is associated with coronary artery vasculitis.
Inflammation in the arterial wall can compromise the structural integrity, which leads to aneu-
rysm formation in 25% of untreated children [7]. The major sequelae of aneurysms include
thrombosis, scarring with stenosis, myocardial ischemia, infarction, and death [8–11]. KD is
over-represented among children of Asian descent. In Japan, the country of highest incidence
(306/100,000 children <5 years; one in every 60 male and 75 female children affected, respec-
tively), there are more than 14,000 new cases each year and rates continue to rise [12]. In the
United States, system dynamic models suggest that by 2030, one in every 1600 adults in the U.
S. will have suffered from KD [13]. Data from limited patient series suggests that African
American is disproportionately affected by KD [14–16]. Despite their apparent increased sus-
ceptibility, children of African American descent has been excluded from previous KD genetic
analyses. As with other complex disorders, elucidation of the genetic determinants of KD has
hitherto relied on candidate gene and genome-wide association studies (GWAS) using
matched population controls and family linkage studies [17–27]. Thus far, many of the associ-
ated genetic variants have been located in introns with no associated molecular function iden-
tified [6]. Only the C allele of SNV rs28493229 in the inositol 1,4,5-trisphosphate 3-kinase C
(ITPKC) gene on chromosome 19q13.2 has been shown to affect gene transcription and impact
intracellular calcium signaling and inflammasome activation [22, 28].
Here, we examined the common disease–rare variant hypothesis in KD in an African
Americans family with two affected and two unaffected siblings and their unaffected, biologic
parents. We report rare, likely pathogenic genotypes in biologically plausible genes that co-seg-
regated with disease in whole genome sequences.
Results
The genomes of all six family members were sequenced with paired, short reads to an aligned
mean read depth of 33.2-fold. Unique nucleotide variants (8,018,553) were identified in the
family, of which 7,592,729 were of high quality (Fig 1). We created three filter pipelines for fur-
ther analysis. First, we applied the following filters: recessive homozygous only in the affected
Whole genome sequencing in Kawasaki disease
PLOS ONE | DOI:10.1371/journal.pone.0170977 February 2, 2017 2 / 17
Funding: National Institute of Health grant
U54HL108460 to LOM; Gordon and Marilyn
Macklin Foundation’s private grant to JCB and AHT;
Rady Children’s Institute for Genomic Medicine,
San Diego. The funders had no role in study
design, data collection and analysis, decision to
publish, or preparation of the manuscript. Although
Dr. Flatley was CEO of Illumina at the time that this
research was initiated, Illumina did not play a role
in the study design, data collection and analysis,
decision to publish, or preparation of the
manuscript and only provided financial support for
the whole genome sequencing. Dr. Flatley’s role
was as a contributor to the interpretation of data
and review of the manuscript.
Competing Interests: Whole genome sequencing
was donated by Jay Flatley who was the CEO of
Illumina at that time. This does not alter our
adherence to PLOS ONE policies on sharing data
and materials.
children, potentially deleterious (located in an exon, promoter region, splice site, or 3’UTR),
and rare (allele frequency <1% or not available in 1,000 Genomes database). To these 34 vari-
ants in 31 genes, we applied two additional filters: gene found in KD pathway (defined by Inge-
nuity Pathway Analysis) and differentially expressed (p<0.05) in our KD transcriptome
database [29]. This identified a CAG repeat variant (CAG10 homozygosity in the two affected
siblings) in myocyte enhancer factor 2A (MEF2A). The reference allele for this variant is CAG11
Fig 1. Workflow of variant discovery and validation. The diagram illustrates a discovery and validation
workflow starting from called variants in an African American family of six members with two KD-affected
children as a discovery analysis on WGS followed by knowledge-based filtering derived from published
GWAS, disease pathogenesis, and gene-level validation using differential transcript abundance. Confidence
filter: a call quality at least 20 and read depth at least 10. Differentially expressed: 1.2-fold change between
acute and convalescent whole blood transcripts. Abbrv.: AF: allele frequency; NA: not available, GWAS:
genome-wide association study; KD: Kawasaki disease; TLR6: Toll-like receptor 6; MEF2A: myocyte
enhancer factor 2A; ARRDC4:arrestin domain containing 4; SLK: STE20 like kinase; TACSTD2: tumor-
associated calcium signal transducer 2.
doi:10.1371/journal.pone.0170977.g001
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and the variant was predicted to be deleterious. The deletion was confirmed by resequencing
all six family members (S1 Table).
An alternative set of filters was applied to the 7,592,729 high quality variants: compound
heterozygous in two affected siblings only, allele frequency <3% in 1000 Genomes database,
found in KD pathway, and differentially expressed in the KD transcriptome database. This
resulted in only two rare variants (p.Leu194Pro and p.Arg247Lys) in a single gene (TLR6) that
were compound heterozygous only in the affected siblings (Table 1). The MEF2A and TLR6
rare and potentially pathogenic variants that were found in KD pathways were grouped
together in Tier 1 (Fig 1 and Table 1). Both TLR6 and MEF2A were differentially expressed in
acute and convalescent whole blood RNA samples, with the highest expression levels in the
acute phase of KD (Fig 2a and 2b).
To explore whether common, deleterious variants were also preferentially associated with
KD, we analyzed 302 recessive homozygous and deleterious variants in 180 genes. Of these,
nine variants in four genes were significantly associated with KD in an imputed European
descent, KD GWAS dataset (nominal p<0.05), and were differentially expressed in whole
blood during acute versus convalescent KD [19, 29]. We used our European descent GWAS
because no published association studies of African Americans KD subjects were available.
These nine common variants were grouped in Tier 2 (Fig 1). Interestingly, TLR6 was one of
the four Tier 2 genes, as well as arrestin domain containing 4 (ARRDC4), STE20 like kinase
(SLK), and tumor-associated calcium signal transducer 2 (TACSTD2). The Tier 2 TLR6 variants
were located either in the promoter or 3’UTR and had population allele frequencies greater
than 3% in the 1,000 Genomes database (risk allele frequency 4.2–63.3%) (Table 1).
eQTL analysis of common TLR6 variants in KD
Among the six genes in the two tiers, TLR6 had multiple variants in both tiers, suggesting that
TLR6 may contribute both to common, sporadic KD as well as uncommon, familial KD. To
explore if there were any additional TLR6 variants for which only the affected children were
homozygous, we re-analyzed the original unfiltered TLR6 WGS from all six family members.
We found 34 additional variants for which only the affected children were homozygous (2
Table 1. Genetic variants found in Tiers 1 and 2.
Tier Mode of inherit Gene Symbol Chr. rs ID Gene Region Risk allele Allelefreq.* GWAS p-value
1 CH TLR6 4 35220466 Exonic C 0.6 NA
1 CH TLR6 4 5743809 Exonic A 1.5 NA
1 HR MEF2A 15 373652230 Exonic CAG deletion NA NA
2 HR TACSTD2 1 14008 Exonic T 15.7 0.01
2 HR TLR6 4 12650224 3’UTR A 21.3 0.002
2 HR TLR6 4 6822503 3’UTR A 63.3 0.008
2 HR TLR6 4 12645200 3’UTR T 63.3 0.008
2 HR TLR6 4 5743826 3’UTR T 4.2 0.003
2 HR TLR6 4 6837101 Promoter A 38.4 0.03
2 HR SLK 10 6584583 Promoter C 83.1 0.01
2 HR SLK 10 10786779 Promoter G 79.3 0.02
2 HR ARRDC4 15 1552673 Promoter C 76.2 0.03
RH = Homozygous Recessive, CH = Compound Heterozygous, TLR6: Toll-like receptor 6, MEF2A: Myocyte Enhancer Factor 2A, TACSTD2: tumor-
associated calcium signal transducer 2, SLK: STE20 like kinase, ARRDC4: arrestin domain containing 4,
* 1000 genome allele frequencies for All, GWAS: European descent GWAS [19], NA: not available
doi:10.1371/journal.pone.0170977.t001
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synonymous exonic SNVs and 32 intronic SNVs)(S2 Table). All were common variants with
allele frequencies of 0.32–0.75 in African datasets in the 1,000 Genomes database. Next, we
looked for association of these 34 variants with KD susceptibility in the imputed European
descent GWAS dataset [19]. There were three intronic SNVs (rs56245262, rs56083757 and
rs7669329) associated with KD susceptibility with p = 6.9x10-6 (S2 Table and Fig 3). These
three intronic SNVs and the seven SNVs in TLR6 from Tiers 1 and 2 are shown in Table 2. The
two SNVs in the 3’UTR (rs6822503 and rs12645200) were in linkage disequilibrium (LD, with
r2 = 0.97 in Africans, r2 = 1 in European descendants) in the imputed European descent
GWAS dataset, as were the three intronic SNVs (rs56245262, rs56083757 and rs7669329), with
r2 = 1 in both African and European descent cohorts. We chose rs6822503 and rs56245262
(earlier chromosome position) as representative SNVs for additional analysis.
To understand the possible effects of common variants in TLR6 in KD pathogenesis, we
performed an eQTL analysis for the two representative SNVs (rs56245262 and rs6822503) and
Fig 2. Paired acute and convalescent whole blood gene expression levels for 131 KD subjects for the
six genes implicated in KD susceptibility. P values are uncorrected. Transcript levels from microarray
database as previously described, not corrected for cell number [29]. Abbrv.: TLR6: Toll-like receptor 6;
MEF2A: myocyte enhancer factor 2A; ARRDC4:arrestin domain containing 4; SLK: STE20 like kinase;
TACSTD2: tumor-associated calcium signal transducer 2.
doi:10.1371/journal.pone.0170977.g002
Fig 3. Location of SNVs associated with KD susceptibility in TLR6. Association results using the imputed
GWAS database were plotted against chromosome location and gene structure of TLR6. Red dots show the
SNVs for which only the affected children were homozygous recessive. SNVs above the blue line were
associated with a P-value <0.05. TLR6 is encoded on the negative strand so the gene structure is shown 3’ to
5’.
doi:10.1371/journal.pone.0170977.g003
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one SNV (rs6837101) in the promoter region of TLR6. Since TLR2/6 activates the transcrip-
tion factors, NFKB and AP1, we focused the eQTL analysis using only the 415 genes targeted
by these transcription factors. For the intronic variant (rs56245262), only one gene (IL6)
among 415 NFKB and/or AP1 targets showed a significant difference in acute whole blood
transcript levels as a function of genotype (nominal p< 0.001). IL6 transcript levels were lower
in subjects homozygous for the risk allele (p = 0.0007 vs. non-risk allele homozygotes, and
p = 0.007 vs. heterozygotes) (Fig 4). For variants in the 3’UTR (rs6822503), no gene showed
significantly different transcript levels as a function of genotype with a p< 0.001. No genes
were regulated as a function of the genotype of the promoter SNV (rs6837101).
Analysis of patient characteristics as a function of genotype
Since the TLR6 intronic SNVs were associated with differential expression of IL6, we reasoned
that patient clinical characteristics related to inflammation might also vary as a function of
genotype. We used our published dataset of 161 subjects [30] with detailed demographic and
clinical information and 7,602,343 imputed genotypes (from the Illumina HumanOmni1-
Quad1 chip) to analyze differences in clinical parameters as a function of genotype for the
Table 2. TLR6 variants in African American family with two affected siblings.
rs ID Gene Region Ethnicity Risk allele Family members WGS GWAS p-value
AA* HIS** ASN CEU KD 1 KD 2 Non-KD 1 Non-KD 2 M F
12650224 3’UTR 0.23 0.17 0.28 0.03 A Hom Hom Het - Het Het Tier2 0.002
6822503 3’UTR 0.77 0.46 0.76 0.52 A Hom Hom Het - Het Het Tier2 0.008
12645200 3’UTR 0.77 0.45 0.76 0.52 T Hom Hom Het - Het Het Tier2 0.008
5743826 3’UTR 0.08 0.02 0 0.01 T Hom Hom Het - Het Het Tier2 0.003
35220466 Exon (p.Arg247Lys) 0.01 0 0 0 T Het Het Het - - Het Tier 1 ND
5743809 Exon (p.Leu194Pro) 0.08 0 0 0 G Het Het - - Het - Tier 1 ND
56245262 Intronic 0.42 0.37 0.62 0.23 A Hom Hom Het - Het Het NA 6.9E-06
56083757 Intronic 0.42 0.37 0.62 0.23 G Hom Hom Het - Het Het NA 6.9E-06
7669329 Intronic 0.42 0.37 0.62 0.23 C Hom Hom Het - Het Het NA 6.9E-06
6837101 Promotor 0.45 0.34 0.35 0.29 A Hom Hom Het - Het Het Tier2 0.03
AA: African American, HIS: Hispanic, ASN: Asian, CEU: European descent, KD: Kawasaki disease affected child, Non-KD: unaffected child, M: mother, F:
father, GWAS: European descent GWAS [19], Hom: homozygous of risk allele, -: homozygous of non-risk allele, NA: not applicable,
* 1000 Genomes African Ancestry in Southwest US,
** 1000 Genomes:Phase_3:AMR
doi:10.1371/journal.pone.0170977.t002
Fig 4. Transcript levels for IL6 in whole blood samples from KD subjects as a function of genotype for
rs56245262 in TLR6. TLR6 rs56245262 risk allele (A) is shown in red. Transcriptome data from a. Acute, pre-
treatment (n = 146: T/T n = 54, T/A n = 69, A/A n = 23), b. Paired acute, pre-treatment and convalescent
(n = 131: T/T n = 53, T/A n = 58, A/A n = 20). P-values were calculated using Mann Whitney test for (a) and
Wilcoxon matched-paired test for (b).
doi:10.1371/journal.pone.0170977.g004
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intronic variant (rs56245262)(Table 3). Homozygosity for the risk allele was more common
among self-declared Asians (10 of 24 (44%) A/A genotype). This result was consistent with the
observation that the A allele frequency is higher in Asian populations (A allele frequencies in
1000 Genome database: Asian 0.62, A/A 0.42, Hispanic 0.37, European descent 0.23). Of inter-
est, the pre-treatment erythrocyte sedimentation rate (ESR) was higher in subjects homozy-
gous for the risk allele (A/A) (median ESR 80 mm/h for A/A vs. 59 mm/h for T/T, p = 0.01).
Discussion
Analysis of WGS of an African Americans family with two affected and two unaffected siblings
and their unaffected, biologic parents highlighted genetic variation in TLR6 in KD susceptibil-
ity. These TLR6 variants included both compound heterozygosity for two rare, likely deleteri-
ous SNVs and homozygosity for common KD risk SNVs. Subsequently, using an acute KD
whole blood transcriptome data set, eQTL analysis of the common SNVs suggested decreased
transcript levels of IL6 and higher ESR at diagnosis in individuals homozygous for the risk
allele. This integrative genomic approach illustrates how WGS in families with multiple
Table 3. Characteristics of subjects (n = 161) by genotype of TLR6 rs56245262.
TLR6 rs56245262 p*
A/A
n = 24
A/T
n = 78
T/T
n = 59
Male, n (%) 15 (63) 48 (62) 33 (56) NS
Age, years median (IQR) 2.7 (0.9–3.8) 2.6 (1.4–4.1) 2.2 (1.2–4.4) NS
Illness Day, median (range)** 6 (3–9) 6 (3–10) 6 (2–10) NS
Ethnicity, n (%)
Asian 10 (44) 13 (17) 5 (8) 0.002***
African-American 1 (0) 5 (6) 0 (0) NS
Caucasian 3 (12) 18 (23) 21 (36) NS
Hispanic 3 (24) 22 (28) 17 (29) NS
More than race 7 (20) 20 (26) 16 (27) NS
Coronary artery status
Aneurysms, n (%) 3 (13) 7 (9) 8 (14) NS
Dilated, n (%) 4 (16) 19 (24) 13 (22)
Normal, n (%) 17 (71) 52 (67) 38 (64)
Z-worst, median (IQR) 1.5 (1.0–2.6) 1.7 (1.1–2.9) 1.9 (1.3–2.9) NS
IVIG resistant, n (%) 4 (17) 19 (25) 12 (20) NS
Lab data, median (IQR)
WBC, ×103/mm3 16.3 (11.6–19.4) 13.2 (10.5–18) 13.9 (11.7–18.7) NS
Absolute neutrophil, ×103/mm3 10.7 (7.4–15.2) 9.0 (6.7–12.5) 8.4 (6.4–11.6) NS
Platelet count, ×103/mm3 401 (334–462) 400 (292–500) 392 (312–472) NS
ESR, mm/h 80 (57–105) 59 (41–80) 59 (44–78) 0.01****
CRP, mg/dl 7.9 (4.3–13.6) 8.4 (4.7–16.8) 8.2 (5.2–16.1) NS
GGT 34 (25–96) 48 (18–134) 41 (22–101) NS
* p-values were calculated by Mann–Whitney U test for continuous variables and chi test for categorical variables except ethnicity comparison.
** Illness day 1: first calendar day of fever.
*** Fisher-Freeman-Halton test. Asian comparing to all other ethnicities combined.
****Mann-Whitney test for the levels of A/A vs. T/T genotype. IVIG: Intra venous immunoglobulin G therapy CRP: C-reactive protein, ESR: Erythrocyte
sedimentation rate, WBC: White blood count
doi:10.1371/journal.pone.0170977.t003
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members affected with a complex genetic disease can yield insights into both the common dis-
ease–common variant and common disease–rare variant hypotheses.
TLR6- NFKB signaling pathway
TLRs recognize pathogen-associated molecular patterns (PAMPS), lead to activation of the
transcription factors, NFKB and AP1, and transcription of genes that control inflammation.
TLR6 forms a heterodimer with TLR2 that recognizes peptidoglycan, diacyl lipoproteins, and
zymosan derived from Gram positive bacteria, mycoplasmas, and fungi, respectively [31].
TLR6 is constitutively expressed in humans on myeloid dendritic cells, monocytes, B cells, cor-
onary artery endothelial cells (EC), and coronary artery vascular smooth muscle cells [32, 33].
In contrast, TLR2 is widely expressed on immune cells but only expressed on human EC and
vascular smooth muscle cells following induction by pro-inflammatory cytokines. Population
differences in downstream cytokine production have been observed following TLR stimula-
tion. In a study of African children, higher levels of TNFα were produced following in vitro
stimulation with a specific TLR2/6 ligand in a whole blood assay when compared to children
of European descent [34].
We found 41 TLR6 variants located in the promoter, intron 1, exon 2, and the 3’UTR asso-
ciated with KD susceptibility. The three common intronic SNVs (rs56245262, rs56083757 and
rs7669329) influenced the transcription of IL6 and were associated with KD susceptibility both
in the European descent GWAS and the African Americans family. IL6, a key cytokine con-
trolled by the transcription factors NFKB and AP1 among others, is reported to be high in the
serum of acute KD patients [35]. Our transcriptome data show that IL6 transcripts are low in
risk allele carriers during the acute disease (Fig 4) [29]. The variants were located in a 1.5kb
region in the middle of the single 28kb intron, 11kb from the splice donor site and 17kb from
the splice acceptor site. Five transcripts of TLR6 have been predicted to result from alternative
splicing (https://www.ncbi.nlm.nih.gov/nuccore?LinkName=gene_nuccore_refseqrna&from_
uid=10333) and it is possible that the intronic SNVs could influence splicing efficiency of these
variants (S1 Fig). The eQTL database, GTEx (http://www.gtexportal.org/home/), showed that
there were tissue-specific effects of these intronic SNVs with the risk allele decreasing TLR6
transcripts in transformed fibroblasts but increasing TLR6 transcripts in a transformed B-cell
line (S2 Fig). No data were available for other tissues of potential interest in KD including
endothelial cells, vascular smooth muscle cells, and cardiomyocytes.
Two of the four TLR6 3’UTR SNVs (rs12645200 and rs6822503) were in LD. We failed to
find any microRNAs that were predicted to bind these four loci according to the miRdSNV
data base (http://mirdSNV.ccr.buffalo.edu/index.php [36] and miRNASNV V2 (http://bioinfo.
life.hust.edu.cn/miRNASNV2/index.php) [37, 38]. For one of the 3’UTR variants, rs6822503,
the risk allele was in weak LD (r2 = 0.58, D’ = 0.94) with the C allele of the exonic variant c.
G1083C (rs3821985) in Africans, and the two affected siblings were homozygous for the C
allele at this locus (S1 Table). Shey et al stimulated whole blood from 70 healthy Africans with
the diacylated lipopeptides, FSL-1 and PAM2 (TLR6/2 ligands), and found reduced IL6 levels
in cells from subjects homozygous for the C allele of rs3821985 compared to G homozygotes
[39]. This finding suggests that our KD-affected siblings might produce lower levels of IL6
upon TLR2/6 stimulation.
The two affected children were compound heterozygotes for the two SNVs in TLR6 exon 2
(p.Leu194Pro and p.Arg247Lys) having inherited the former from the mother and the latter
from the father. These SNVs change amino acids located on the extracellular surface of TLR6
in a region predicted to be involved with ligand binding, which could influence ligand-binding
affinity (Fig 5). 3D proteomic structure modeling of the two non-synonymous mutations was
Whole genome sequencing in Kawasaki disease
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computationally predicted (SNPs3D: http://www.snps3d.org/modules.php?name=
SnpAnalysis&locus_ac=10333). p.Leu194Pro is predicted to be deleterious due to loss of an
intramolecular hydrogen bond and p.Arg247Lys is a variant classified as non-deleterious but
on the protein ectodomain. The functional impact of these TLR6 variants was tested using an
NF-κB luciferase reporter assay in human embryonic kidney 293T cells expressing the TLR6
variants and stimulated with TLR agonists [40]. p.Arg247Lys showed a 15.6% decrease in abil-
ity to respond to the TLR2/6 agonist, PAM2CSK4. Cells transfected with p.Leu194Pro con-
structs showed a more marked decrease in NF-kB activation (25.4%). Thus, compound
heterozygosity for these SNVs in the affected children is expected to reduce NF-kB activation.
Role of NFKB and IL6 in the modulation of immune responses
A self-limited inflammatory disease like KD must activate potent anti-inflammatory pathways
that ultimately lead to the resolution of inflammation. TLR2/6 stimulation initiates inflamma-
tion but also stimulates the regulatory compartment of the immune response. In mice, stimu-
lation of TLR2/TLR6 expressed on dendritic cells leads to their differentiation into tolerogenic
dendritic cells secreting IL-10 and promotes T cell differentiation into a regulatory (Treg) phe-
notype [41]. Work by Franco et al. has highlighted the importance of IL-10 secretion by natu-
ral regulatory T cells and tolerogenic myeloid dendritic cells in the resolution of inflammation
in KD patients [42, 43]. Downstream of TLR2/6, both NFKB and IL6 have complex immune
functions [44, 45]. In the carrageenan-induced rat pleurisy model, blocking NFKB led to pro-
tracted inflammation with reduced leukocyte apoptosis and decreased release of the anti-
inflammatory molecule, TGFβ1, thus highlighting the important role of NFKB in the resolu-
tion of inflammation [44].
IL6 functions by binding the IL6 receptor (R) and gp130, a transmembrane signal transduc-
tion protein. The IL6R is expressed only on hepatocytes and a subset of inflammatory cells
including macrophages, neutrophils, and naïve T cells. However, gp130 is ubiquitously
expressed [45]. During acute inflammation, neutrophils infiltrate tissues and undergo apopto-
sis with shedding of IL6-sIL6R. This complex binds gp130 on endothelial cells leading to signal
transduction that results in monocyte/macrophage recruitment and removal of apoptotic neu-
trophils. Thus, reduced levels of IL6 might be expected to allow persistence of neutrophils in
the arterial wall and in the circulation. Although IL6 levels in the serum are high in acute KD,
Fig 5. TLR6 exonic SNV positions. Positions of the exonic SNVs rs5743809 and rs3522046 on the TLR6
protein diagrammed using NCBI Molecular Modeling database (MMDB). The replaced amino acids (p.
Leu194Pro and p.Arg247Lys) are shown in green. Variants are located in the extra-cellular domain in the
predicted ligand-binding region and may alter hydrogen binding.
doi:10.1371/journal.pone.0170977.g005
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this may represent synthesis of IL6 by hepatocytes as part of the acute phase response rather
than synthesis by circulating immune cells as eQTL are often tissue-specific [35]. This could
have important implications for persistence of the acute inflammatory state in KD (Fig 6). Of
interest, a pilot study of tocilizumab (monoclonal antibody against human IL6R) plus IVIG for
treatment of acute KD was terminated for safety concerns when the first three patients enrolled
developed CAA (Prof. Emeritus Shumpei Yokota, Yokohama City University, Japan, personal
communication).
Tier 1 genes
TLR6 and the transcription factor, MEF2A, were the two Tier 1 genes. They were found in KD
pathways and were differentially expressed in the KD transcriptome database with significantly
higher levels in the acute phase. MEF2A plays a critical role in transcriptional activation of IL-
2 during T cell activation [46]. Our associated SNV, rs373652230, was a (CAG) deletion at
amino acid 420 in a poly-lysine tract and multiple studies have reported (CAG)n variants asso-
ciated with coronary artery disease, although the mechanism underlying this association has
not been elucidated [47]. Although the Ingenuity Variant Analysis identified the CAG10 vari-
ant as rare (allele frequency<1%), studies in European descent, Asian, and Turkish popula-
tions found allele frequencies from 12.7–21.9%. We were unable to find data regarding the
allele frequency of the (CAG) repeats in African Americans populations. Of interest, the intro-
nic TLR6 SNV, rs56083757 and the promoter SNV rs6837101, were also predicted to influence
the DNA binding of MEF2A (HaploReg: http://www.broadinstitute.org/mammals/haploreg/
detail_v4.1.php?query=&id=rs56083757). No other functional significance could be assigned
to the other SNVs.
The nature of the PAMP that might stimulate TLR6/TLR2 in KD is unknown although a
hypothesis has linked KD to inhalation of Candida antigens carried on aerosols arising from
agricultural areas in China [48]. Of speculative interest, the glucans from the Candida cell wall
are potent ligands for TLR2/6. In addition, C57BL/6 mice are homozygous for the p.
Fig 6. Hypothetical role of decreased IL6 signaling in the persistence of vascular inflammation in
acute KD. The TLR6 variants associated with KD are predicted to yield lower levels of NFKB upon
stimulation, thus resulting in lower levels of IL6. During vascular inflammation, neutrophil apoptosis is
associated with shedding of the soluble IL6R-IL6 complex, which binds to gp130 on endothelial cells. This
stimulates a signaling pathway that switches the adhesion molecule and chemokine profile to one that favors
attraction of monocytes to the vessel wall with subsequent downregulation of vascular inflammation. In KD,
lower levels of IL6 may lead to persistence of neutrophil recruitment to the vessel wall and prolonged
inflammation.
doi:10.1371/journal.pone.0170977.g006
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Leu194Pro variant in TLR6 and two murine models of coronary artery vasculitis in this species
use intraperitoneal injection of either Candida albicans or Lactobacillus casei cell wall extracts,
both of which are potent ligands for TLR2/6[49, 50].
Tier 2 genes
Six genes harboring nine variants met the criteria of homozygous recessive, predicted deleteri-
ous, significantly associated in the imputed GWAS, and differentially expressed in acute versus
convalescent KD (Fig 2). The TLR6 promoter and 3’UTR SNVs were discussed above.
The Tier 2 gene, TACSTD2, is involved in calcium signaling and may be linked in this way
to KD pathogenesis. Validated calcium signaling genes linked to KD pathogenesis currently
include ITPKC, ORAI1, and SLC8A1 [22, 30, 51]. TACSTD2 encodes for Trop2, a membrane-
spanning protein that transduces an intracellular calcium signal. The protein is over-expressed
in many epithelial cancers and is thought to be involved in metastasis and malignant cell inva-
sion [52]. Its transcription is regulated by a number of transcription factors including NFKB
and its expression was high in acute versus convalescent KD.
The serine/threonine Ste-like protein kinase, SLK, belongs to the family of germinal center
kinases, is ubitquitously expressed, and is involved with stress-induced apoptosis, cytoskeletal
remodeling, and cell motility [53]. ARRDC4 is a member of the α-arrestin family, which, as a
class, is involved with fine-tuning cellular responses to cell surface signals [54]. Both SLK and
ARRDC4were transcriptionally upregulated in acute KD but the mechanism through which
these genes may participate in KD susceptibility is unclear.
Strengths and limitations
This is the first analysis of WGS in an African Americans family and provides a database that
can be mined for future studies of genetic structure in this population. Many different filters
can be applied for subsequent analyses that may uncover additional variants that influence sus-
ceptibility to KD. Neither affected child developed coronary artery aneurysms, so only variants
affecting susceptibility can be analyzed from this dataset. We recognize that using a whole
blood transcriptomic database from a mixed ethnic population could miss transcripts that are
only differentially expressed in relevant cardiovascular tissues and among African Americans.
This analysis underscores the need to focus genetic and genomic studies on minority popula-
tions such as African Americans who are disproportionately affected by KD compared to chil-
dren of European descent.
Conclusion
The first analysis of WGS from an African Americans family with two siblings affected with
KD revealed genetic variation in TLR6 that may be linked to the pro-inflammatory state during
acute KD. Previous GWAS and linkage association studies had not identified this gene as influ-
encing susceptibility to KD. Another variant, in TACSTD2, has an intriguing link to calcium
signaling that will need to be pursued in future studies. The analytic approach presented here
is a novel method for finding potentially relevant variants in WGS in families with individuals
affected by complex genetic diseases.
Materials and methods
Subjects
Members of the African American family selected for whole genome sequencing included two
affected sons, an older unaffected son and daughter, and unrelated/unaffected father and
Whole genome sequencing in Kawasaki disease
PLOS ONE | DOI:10.1371/journal.pone.0170977 February 2, 2017 11 / 17
mother, all of whom provided written informed consent for study participation. The study was
approved by the Institutional Review Board at the University of California San Diego. The two
affected subjects were both diagnosed by one of the co-authors (JCB). Neither developed coro-
nary artery abnormalities by echocardiogram and both responded to a single dose of IVIG
with defervescence and resolution of inflammation.
Whole genome sequencing
Whole blood samples or Scope1 mouthwash rinses were obtained from family members and
10 μg of genomic DNA was extracted and submitted to Illumina Clinical Services Laboratory
in San Diego, CA, USA for sequencing using HiSeq 2000. DNA was fragmented and attached
to the surface of glass microscope slides. Fluorescently labeled nucleotides were used to
sequence the fragments. Laser excitation of the nucleotides was followed by digital imaging.
The sequence fragments were assessed for quality scores.
Sequence processing and variant calling
Raw images were processed by Illumina’s CASAVA version 1.8 pipeline to generate six sample
FASTQ files for a downstream analysis. The FASTQ files were aligned to a human reference
genome (hg19), PCR duplicates marked and variants called using Edico Genome’s DRAGEN
pipeline [55], using default parameters.
Variant prioritization
VCF files were uploaded to Ingenuity Variant Analysis™ (QIAGEN Redwood City, CA) for ter-
tiary analysis. Variant prioritization was performed by sequentially applying filters in 7 steps of
confidence, genetics (recessive homozygous and compound heterozygous), predicted deleteri-
ous, rare, found in KD pathway, significant in published KD GWAS, and differentially
expressed in KD transcriptome database (Fig 1). The Confidence filter retained variants with a
call quality at least 20, read depth at least 10, and eliminated the top 5% of the most exonically
variable genes or 100-bp regions in 1000 Genomes to remove false positive variants such as
mucin and olfactory receptor genes. The annotated variants were imported into an in-house
MySQL database to perform genetic analysis of two inheritance types, recessive homozygous
and compound heterozygous. The Homozygous filter required homozygous variants to be pres-
ent exclusively in the two KD affected children but not in any of the four unaffected individu-
als. The Compound heterozygous filter was constructed based on the following rules [56]:
1. A variant is in a heterozygous state in both of KD affected children.
2. A variant must not occur in a homozygous state in any of the four unaffected individuals,
i.e. two siblings and two parents.
3. A variant that is in a heterozygous state in an affected child must be heterozygous in exactly
one of the parents but not both.
The Predicted deleterious filter followed the guideline classification of American College of
Medical Genetics (ACMG) and loss-of-function in terms of frameshift, in-frame in/del, start/
stop codon change, missense, or splice site loss all implemented in IVA. The Rare filter
retained variants whose allele frequency was less than 1% (for recessive homozygosity) or 3%
(for compound heterozygosity) in any of three public datasets; 1000 genomes, Exome Aggrega-
tion Consortium (ExAC), and NHLBI ESP Exomes. The Pathway filter generated by Ingenuity
program retained genes implicated in pathways relevant to KD pathogenesis. These were
defined using the Ingenuity system with the key terms “susceptibility to KD”, “calcium
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signaling pathway, coronary artery aneurysm”, and “coronary artery abnormalities”. The
GWAS filter retained variants that were significantly (nominal P-value < 0.05) associated in
405 KD subjects versus 6,252 normal controls in our previously published KD GWAS dataset
genotyped on the Illumina HumMap 550 SNV array [19]. Since GWAS targets common SNVs
with an allele frequency > 5%, the GWAS filter was applied to variants surviving the Deleteri-
ous filter in Fig 1. Quality control was performed with missing rate, minor allele frequency
(MAF) and Hardy-Weinberg Equilibrium (HWE) cutoff values. The original dataset was
expanded through imputation using SHAPEIT2 for phasing and IMPUTE2 for imputation
with the most recent versions of 1000 Genomes version 3 and HapMap3 CEU panels (hg18) as
reference data. LiftOver tool from UCSC Genome Browser (Kent et al. Genome Res 2002
PMID:12045153) was used to convert genomes coordinates from assembly hg18 to hg19. The
new imputation with updated reference panels increased the total number of imputed SNVs to
7,602,343 from 4,545,265. The Transcriptome filter set gene-level prioritization by retaining
differentially expressed genes between 131 paired acute and convalescent whole blood RNA
samples (PAXgene).[29] Transcript levels were measured using the Illumina HumanRef-12 V4
BeadChip with 47,000 probes and quality control and analysis were as described. The cutoff
for differential expression was an adjusted P-value < 0.05.
Validation genotyping
MEF2A. The six family members were re-sequenced for the MEF2A (CAG)n variant.
Primers were designed using Primer 3: forward primer (caagtccgaaccgatttcac) and reverse
primers (gccaagcacaattggagaat) (product size 247 bp). Fifty nanograms of DNA from each
sample was amplified using high-fidelity Taq polymerase (Platinum1 Taq DNA Polymerase
High Fidelity, Life Technologies) for 35 cycles following the manufacturer’s instructions. PCR
products were resolved on 2% agarose gels, excised, and purified (QIAquick Gel Extraction
Kit, Qiagen). PCR products were sequenced using forward and reverse primers (Eaton Biosci-
ence Inc., San Diego).
eQTL analysis
Detailed methods were described previously [30]. A total of 673 probes from 415 genes from
the database of literature-curated human TF-target interactions for NFKB and AP1 were used
for eQTL analysis [57].
Data sharing
Data is available upon request. Users wishing to access our data should contact us.
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